Mukka Proteins Limited has entered into a loan agreement with its subsidiary, United Gulf Fishery Products LLC, to provide financial assistance for urgent business commitments. The company will extend an unsecured loan of up to Rs 9.10 crore to the subsidiary at an interest rate of 8% per annum. The tenure for the loan is set at five years from the date of disbursal.

The loan agreement was executed on July 9, 2026. As of the date of disclosure, the total amount outstanding under this facility stands at Rs 3,01,22,744.17. The transaction is classified as a related party transaction and has been conducted on an arm’s length basis.

Mukka Proteins holds a 68% stake in United Gulf Fishery Products LLC. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Key Details of the Loan Agreement

The filing was signed by Mehaboobsab Mahmadgous Chalyal, Company Secretary & Compliance Officer of Mukka Proteins Limited.

Mukka Proteins has issued a corrigendum to its postal ballot notice for the proposed preferential issue of 2,00,00,000 convertible warrants, aggregating up to ₹470 crore. The update follows observations received from the National Stock Exchange of India Limited (NSE) on June 17, 2026, and June 29, 2026, and BSE Limited on June 29, 2026, regarding the issuance. The company has clarified the utilization of proceeds and the pricing basis for the warrants, which are being offered to shareholders for approval.

The corrigendum was sent to members on July 06, 2026, by electronic means. Newspaper advertisements regarding the completion of the dispatch of the corrigendum were published on July 07, 2026, in Business Standard and Vijaya Karnataka. The document forms an integral part of the original notice dated June 12, 2026.

The preferential issue involves the issuance of 2,00,00,000 convertible warrants at a price of ₹23.50 per warrant. The proceeds, totaling ₹470 crore, are proposed to be allocated across working capital requirements, business expansion, and general corporate purposes. The company stated that the allocation provides flexibility to support long-term growth and operational scale.

Pricing and Valuation

The issue price of ₹23.50 per warrant was determined based on the higher of the floor price calculated under Regulation 164(1) of the SEBI ICDR Regulations and the fair value determined by an independent registered valuer. The floor price was calculated at ₹23.18 per equity share, derived from the 90-day volume weighted average price (VWAP) on the NSE. The fair value, assessed by Ms. Kavita Joshi, Chartered Accountant and Registered Valuer, was determined at ₹18.14 per share using the cost, income, and market approaches.

The Board of Directors approved the issue price of ₹23.50, which exceeds the minimum price determined under the applicable regulations. The company confirmed that the proposed preferential issue does not exceed 5% of the post-issue fully diluted share capital and does not result in any change in control or management.

Regulatory Compliance and Shareholder Action

The corrigendum was issued in compliance with the observations from the stock exchanges and the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The revised valuation report dated July 03, 2026, and a certificate from a practicing company secretary confirming compliance with ICDR Regulations have been made available on the company's website.

Shareholders who have already cast their votes in the ongoing postal ballot but wish to modify their decision in light of the corrigendum may do so by emailing the scrutinizer at cs@cnassociates.in , with a copy to helpdesk.evoting@cdslindia.com . Requests must be submitted by 5:00 PM IST on July 12, 2026, to be considered for the scrutinizer's report.